Lipitor
This suit looked to prove Pfizer’s promotion of Lipitor has created an artificial demand for the drug Lipitor that did not benefit its users. On 28 September 2005, a class action suit was filed against pharmaceutical company Pfizer for launching an aggressive but misleading advertising campaign to promote Liptor, a cholesterol lowering drug.
It was marketed as an effective way to reduce the risk of heart disease and diabetes for women under 65 or individuals over 65 who have not previously been diagnosed with heart disease or diabetes, when there was no evidence to support this claim.
Lipitor is a widely used statin drug that reaped a phenomenal $12 billion in 2003. This suit looked to prove Pfizer’s promotion of Lipitor has created an artificial demand for the drug Lipitor that did not benefit its users.
This class action suit was filed by several individuals and organizations such as Health Care For All and the Pennsylvania Benefit Trust Fund in the US District Court for the District of Delaware.
Related posts:
Sphere: Related Content
Leave a Reply